Treatment of NSCLC cell lines with IL22 enhances proliferation, migration, and invasion via activation of IL22R1/STAT3 signaling, while siRNA-mediated depletion of IL22R1 abrogates the effects of IL122 on cell proliferation and migration [192]. Here, STAT3 is linked to non-small cell lung carcinoma.